Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

Goldstein LJ, Perez RP, Yardley D, Han LK, Reuben JM, Gao H, McCanna S, Butler B, Ruffini PA, Liu Y, Rosato RR, Chang JC.

Breast Cancer Res. 2020 Jan 10;22(1):4. doi: 10.1186/s13058-019-1243-8.

2.

Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies.

Perez RP, Chen E, Thaddeus Beck J, Shirai K, Neil Hayes D, Shen T, Baldwin JR, Bryant KB, He S, Chin S.

Pharmacol Res Perspect. 2019 Nov 25;7(6):e00519. doi: 10.1002/prp2.519. eCollection 2019 Dec.

3.

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.

Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS.

Clin Cancer Res. 2020 Jan 15;26(2):344-353. doi: 10.1158/1078-0432.CCR-19-0647. Epub 2019 Oct 31.

PMID:
31672767
4.

Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors.

Mileham KF, Schenkel C, Chuk MK, Buchmeier A, Perez RP, Hurley P, Levit LA, Garrett-Mayer E, Davis C, Bruinooge SS, Vose J.

J Oncol Pract. 2019 Dec;15(12):e1050-e1065. doi: 10.1200/JOP.19.00366. Epub 2019 Oct 24.

PMID:
31647695
5.

Changes in the vertical distribution of leaf area enhanced light interception efficiency in maize over generations of selection.

Perez RPA, Fournier C, Cabrera-Bosquet L, Artzet S, Pradal C, Brichet N, Chen TW, Chapuis R, Welcker C, Tardieu F.

Plant Cell Environ. 2019 Jul;42(7):2105-2119. doi: 10.1111/pce.13539. Epub 2019 Apr 17.

PMID:
30801738
6.

Designing oil palm architectural ideotypes for optimal light interception and carbon assimilation through a sensitivity analysis of leaf traits.

Perez RPA, Dauzat J, Pallas B, Lamour J, Verley P, Caliman JP, Costes E, Faivre R.

Ann Bot. 2018 Apr 18;121(5):909-926. doi: 10.1093/aob/mcx161.

7.

Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.

Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM.

J Clin Oncol. 2018 Feb 20;36(6):617-623. doi: 10.1200/JCO.2017.75.8193. Epub 2017 Dec 13. No abstract available.

PMID:
29236570
8.

Post-operative outcomes of surgical and chemical castration with zinc gluconate in dogs presenting to veterinary field clinics.

DiGangi BA, Grijalva J, Jaramillo EPP, Dueñas I, Glenn C, Cruz MEC, Pérez RPM.

Vet J. 2017 Nov;229:26-30. doi: 10.1016/j.tvjl.2017.10.016. Epub 2017 Nov 6.

PMID:
29183570
9.

Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

Komiya T, Yamamoto S, Roy A, McDonald P, Perez RP.

Transl Lung Cancer Res. 2017 Oct;6(5):600-610. doi: 10.21037/tlcr.2017.07.02.

10.

The RS4939827 polymorphism in the SMAD7 GENE and its association with Mediterranean diet in colorectal carcinogenesis.

Alonso-Molero J, González-Donquiles C, Palazuelos C, Fernández-Villa T, Ramos E, Pollán M, Aragonés N, Llorca J, Henar Alonso M, Tardón A, Amiano P, Moleon JJJ, Pérez RP, Capelo R, Molina AJ, Acebo IG, Guevara M, Perez-Gomez B, Lope V, Huerta JM, Castaño-Vinyals G, Kogevinas M, Moreno V, Martín V.

BMC Med Genet. 2017 Oct 30;18(1):122. doi: 10.1186/s12881-017-0485-5.

11.

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.

Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ.

Gynecol Oncol. 2017 Nov;147(2):402-407. doi: 10.1016/j.ygyno.2017.08.015. Epub 2017 Aug 24.

12.

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.

Schott AF, Goldstein LJ, Cristofanilli M, Ruffini PA, McCanna S, Reuben JM, Perez RP, Kato G, Wicha M.

Clin Cancer Res. 2017 Sep 15;23(18):5358-5365. doi: 10.1158/1078-0432.CCR-16-2748. Epub 2017 May 24.

13.

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.

Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ.

Cancer. 2017 Aug 15;123(16):3080-3087. doi: 10.1002/cncr.30736. Epub 2017 Apr 25.

14.
15.

It May Be Too Early to Try to Prove the Effect of Deworming on Tuberculin Reactivity.

Pérez RP, Sáinz-Costa T, Mellado-Peña MJ.

Pediatr Infect Dis J. 2017 Feb;36(2):241. doi: 10.1097/INF.0000000000001401. No abstract available.

PMID:
28079837
16.

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ.

J Clin Oncol. 2017 Apr 1;35(10):1112-1118. doi: 10.1200/JCO.2016.69.9538. Epub 2016 Dec 28.

17.

Integrating mixed-effect models into an architectural plant model to simulate inter- and intra-progeny variability: a case study on oil palm (Elaeis guineensis Jacq.).

Perez RP, Pallas B, Le Moguédec G, Rey H, Griffon S, Caliman JP, Costes E, Dauzat J.

J Exp Bot. 2016 Aug;67(15):4507-21. doi: 10.1093/jxb/erw203. Epub 2016 Jun 14.

PMID:
27302128
18.

TP53 Gene and Cancer Resistance in Elephants.

Perez RP, Komiya T.

JAMA. 2016 Apr 26;315(16):1789-90. doi: 10.1001/jama.2016.0446. No abstract available.

PMID:
27115384
19.

Systematic analysis of design and stratification for phase III trials in first-line advanced non-small cell lung cancer.

Komiya T, Perez RP, Erickson KD, Huang CH.

Thorac Cancer. 2016 Jan;7(1):66-71. doi: 10.1111/1759-7714.12276. Epub 2015 May 12.

20.

Primary lung mucoepidermoid carcinoma: analysis of prognostic factors using surveillance, epidemiology and end results program.

Komiya T, Perez RP, Yamamoto S, Neupane P.

Clin Respir J. 2017 Nov;11(6):847-853. doi: 10.1111/crj.12426. Epub 2016 Jan 6.

PMID:
26663856
21.

Infrequent chemoradiation-induced acute esophagitis in the Asian population: A meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer.

Komiya T, Palla SL, Wang F, Perez RP, Huang CH.

Thorac Cancer. 2014 Nov;5(6):565-9. doi: 10.1111/1759-7714.12141. Epub 2014 Oct 23.

22.

[Rheumatic fever versus post-streptococcal reactive arthritis. What would you say, Jones?].

Verrier EC, Ormaechea NL, Pérez RP, Sánchez-Manjavacas AS, López AL, Ortega MJ.

An Pediatr (Barc). 2012 Mar;76(3):178-9. doi: 10.1016/j.anpedi.2011.11.010. Epub 2011 Dec 24. Spanish. No abstract available.

23.

Clinical inertia in diagnosis and treatment of hypertension in primary care: quantification and associated factors.

Gil-Guillén V, Orozco-Beltrán D, Pérez RP, Alfonso JL, Redón J, Pertusa-Martínez S, Navarro J, Cea-Calvo L, Quirce-Andrés F, Merino-Sánchez J, Carratalá C, Martín-Moreno JM.

Blood Press. 2010 Feb;19(1):3-10. doi: 10.3109/08037050903350762.

PMID:
19929287
24.
25.

Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.

Mita AC, Olszanski AJ, Walovitch RC, Perez RP, MacKay K, Tuck DP, Simmons C, Hammond S, Mita MM, Beeram M, Stone AJ, Rowinsky EK, Lewis LD.

Clin Cancer Res. 2007 Jun 1;13(11):3293-301.

26.

Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).

Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A.

Clin Cancer Res. 2006 Dec 1;12(23):7079-85.

27.

New targets and challenges in the molecular therapeutics of cancer.

Eastman A, Perez RP.

Br J Clin Pharmacol. 2006 Jul;62(1):5-14.

28.

Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma.

Pipas JM, Barth RJ Jr, Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, Cates JM, Ripple GH, Sutton JE, Gordon SR, McDonnell CE, Perez RP, Redfield N, Meyer LP, Marshall JF, Cole BF, Colacchio TA.

Ann Surg Oncol. 2005 Dec;12(12):995-1004. Epub 2005 Nov 1.

PMID:
16252135
29.

Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.

Ramanathan RK, Fakih M, Mani S, Deutsch M, Perez RP, Ritter MA, Eiseman JL, Ivy SP, Trump DL, Belani CP, Parise RA, Potter DM, Egorin MJ.

Cancer Chemother Pharmacol. 2006 Apr;57(4):465-74. Epub 2005 Aug 25.

PMID:
16133531
30.

Risk factors for asymptomatic bacteriuria in women with diabetes.

Ribera Montés Mdel C, Pérez RP, Barba CP, Beltrán DO, Carbonell VP.

Clin Infect Dis. 2004 Dec 1;39(11):1732-3; author reply 1733-4. No abstract available.

PMID:
15578383
31.

The effects of ethidium bromide induced loss of mitochondrial DNA on mitochondrial phenotype and ultrastructure in a human leukemia T-cell line (MOLT-4 cells).

Armand R, Channon JY, Kintner J, White KA, Miselis KA, Perez RP, Lewis LD.

Toxicol Appl Pharmacol. 2004 Apr 1;196(1):68-79.

PMID:
15050409
32.

Ubiquinone does not rescue acute myeloid leukemia cells from growth inhibition by statins.

Burke LP, Lewis LD, Perez RP.

Leukemia. 2003 Jan;17(1):267-8. No abstract available.

PMID:
12529692
33.

Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.

Pipas JM, Mitchell SE, Barth RJ Jr, Vera-Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1317-22.

PMID:
11483344
34.

RT-PCR Quantitation of HSP60 mRNA Expression.

Perez RP, Pendyala L, Elakawi Z, Abu-Hadid M.

Methods Mol Med. 2001;39:439-47. doi: 10.1385/1-59259-071-3:439.

PMID:
21340800
35.

Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens.

Perez RP, Zhang P, Bosserhoff AK, Buettner R, Abu-Hadid M.

Hum Pathol. 2000 Nov;31(11):1381-8.

PMID:
11112213
36.

Credentialing residents for intraoperative cystoscopy.

Hibbert ML, Salminen ER, Dainty LA, Davis GD, Perez RP.

Obstet Gynecol. 2000 Dec;96(6):1014-7.

PMID:
11084196
37.

Development of a core curriculum in professional growth: practice management military model.

Perez RP, Brown FB, Salminen ER, Hume RF, Wittich AC.

Mil Med. 1999 Nov;164(11):764-6.

PMID:
10578585
38.
39.

Enhancing advanced surgical laparoscopy. Combined, routine use of microlaparoscopes and macrolaparoscopes.

Hibbert ML, Palacio PE, Larsen FW, Davis GD, Perez RP.

J Reprod Med. 1999 Jan;44(1):1-6.

PMID:
9987731
40.

Female circumcision: the prevalence and nature of the ritual in Eritrea.

Davis G, Ellis J, Hibbert M, Perez RP, Zimbelman E.

Mil Med. 1999 Jan;164(1):11-6.

PMID:
9922637
41.

Cellular and molecular determinants of cisplatin resistance.

Perez RP.

Eur J Cancer. 1998 Sep;34(10):1535-42. Review.

PMID:
9893624
42.
43.

Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors.

Creaven PJ, Raghavan D, Perez RP, Pendyala L, Berghorn EJ Jr, Loewen G, Meropol NJ.

Semin Oncol. 1996 Dec;23(6 Suppl 16):26-31.

PMID:
9007117
44.

Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.

O'Dwyer PJ, Perez RP, Yao KS, Godwin AK, Hamilton TC.

Biochem Pharmacol. 1996 Jul 12;52(1):21-7.

PMID:
8678904
45.

[Prostatic non-Hodgkin's lymphoma: report of a new case].

Fernández Marichal F, Pérez RP, Pila Peláez RP, Chávez Olivera R.

Arch Esp Urol. 1996 Jun;49(5):521-3. Spanish.

PMID:
8766091
46.

Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.

Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, Caligiuri MA.

Clin Cancer Res. 1996 Apr;2(4):669-77.

47.

Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute.

Wilkes JD, Fidias P, Vaickus L, Perez RP.

Cancer. 1995 Oct 15;76(8):1377-87. Review.

PMID:
8620412
48.

Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells.

Perez RP, Johnson SW, Handel LM, O'Dwyer PJ, Hamilton TC.

Gynecol Oncol. 1995 Sep;58(3):312-8.

PMID:
7672697
49.

Soft tissue sarcomas in adults.

Karakousis CP, Perez RP.

CA Cancer J Clin. 1994 Jul-Aug;44(4):200-10. Review.

50.

Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.

Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC.

Biochem Pharmacol. 1994 Feb 11;47(4):689-97.

PMID:
8129746

Supplemental Content

Loading ...
Support Center